Table 4.

Overview of the application of FMT in cancer therapy.

Cancer type	Intervention	Therapy regimen	Object	Purpuse	Results	References
	FMT	5-FU	Cancer patients	Reduce side-effect	Attenuated body weight loss Attenuated the shortening of colon Ameliorated dysbiosis	Li et al., (2017)
	FMT	Radiotherapy	Mouse models		Increased the survival rate of irradiated animals Elevated peripheral white blood cell counts Improves GI tract barrier function and epithelial integrity Ameliorated dysbiosis Retained the gene expression profile of the small intestine Enhanced angiogenesis without accelerating tumor growth	Cui et al., (2017)
	FMT	Radiotherapy	Cancer patients		Ameliorated rectal hemorrhage, fecal incontinence, diarrhea and abdominal and rectal pain Reduction in Radiation Therapy Oncology Group (RTOG/EORTC) late toxicity grade from baseline Ameliorated dysbiosis	Ding et al., (2020)
Urothelial carcinoma, prostate cancer	FMT	CTLA-4 and PD-1 CTLA-4	Cancer patients		Complete resolution of clinical symptoms Attenuated mucosal inflammation and ulceration Ameliorated dysbiosis	Wang et al., (2018)
Metastatic melanoma	FMT	PD-1	Cancer patients	Improve efficacy	Overcame resistance to anti-PD-1 Longer median progression-free survival Ameliorated dysbiosis Enhanced antitumor immunity	Baruch et al., (2021)
Melanoma	FMT	PD-1	Cancer patients		Overcame resistance to anti-PD-1 Ameliorate dysbiosis Enhanced antitumor immunity Lower inflammatory cytokines	Davar et al., (2021)

Abbreviations: CTLA-4, cytotoxic T lymphocyte associated protein 4.